DiaCardia, a novel artificial intelligence model that can accurately identify individuals with prediabetes using either ...
TORONTO, ON / ACCESS Newswire / January 20, 2026 / NeuralCloud Solutions Inc. ("NeuralCloud"), a subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML) (OTCQB:AIMLF) (FWB:42FB), is ...
AliveCor announced today that it received FDA clearance for the next generation of its AI technology for the Kardia 12L ECG ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leading artificial intelligence (AI)-driven health technology company, announced that the Centers for Medicare & Medicaid Services (CMS) has included its ...
MOUNTAIN VIEW, Calif., June 25, 2024 /PRNewswire/ -- AliveCor, the global leader in AI-powered cardiology, today announced the U.S. Food & Drug Administration (FDA) clearance and commercial launch of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, announced today it has received the 2024 MedTech Breakthrough Award ...
This will enable the Company to efficiently validate real-world performance of the HeartBeam System and establish reference ...
Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. (HSCS) d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company ...
HeartSciences Inc., an AI-powered medical technology company focused on transforming ECGs for earlier heart disease detection, provided a financial update for the third quarter of fiscal 2025, ...
PulseAI's technology, trained on large-scale ECG datasets and validated in partnership with some of the world's leading institutions across Europe and the United States, promises to bring the power of ...
Sudden cardiac events (SCEs) are the leading cause of line-of-duty deaths (LODDs) among firefighters in the United States, so it is obvious why there is such an appeal for electrocardiogram (ECG) ...
HeartSciences is on track for a significant innovation in the healthcare space with the development of its MyoVista® wavECG™ device, which is approaching FDA submission, indicating progress toward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results